Women with a history of breast cancer have a one in five chance that the cancer will recur within 10 years of treatment. With that in mind, researchers have developed a blood test that can detect cancer recurrence sooner and with more sensitivity than previous blood tests.
Magnetic resonance imaging can be helpful and cost-effective in detecting breast cancer in certain patient populations, according to new research presented at the 8th European Breast Cancer Conference in Vienna, Austria.
Group cognitive behavioral therapy (CBT) is an effective tool in reducing menopause-related symptoms in women with a history of breast cancer, according to new research published in The Lancet Oncology.
Over the past few years, there has been great concern over the presence of alkyl esters of p-hydroxybenzoic acid (parabens) in consumer products and their link to breast cancer. These compounds have been found in human blood, milk, urine, and breast tissue.
Findings published in the latest issue of Cancer Prevention Research suggest that antiestrogen supplements help decrease the risk of subsequent melanoma in patients with breast cancer.
As a gynecological oncologist, I often see patients who want to be tested for cancer because a close family member has just been diagnosed. Understandably, they want to be sure they don’t have it.
Decreases in bone mineral density and an increased risk of arthritis may be linked to bilateral oophorectomy, according to new research presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
Lymphedema, swelling caused by a blockage in the lymphatic system, can occur as a result of surgical or radiation therapy associated with breast cancer treatment. Since some research has shown that exercise after breast cancer treatment has been associated with developing lymphedema, clinicians often advise patients to avoid exercising. But is this truly necessary?
This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.
In an expected move, the FDA has withdrawn its accelerated approval of Avastin (bevacizumab) for the treatment of breast cancer. Specifically, bevacizumab is no longer indicated for use in combination with paclitaxel for patients with HER2-negative metastatic breast cancer who have not undergone chemotherapy.